CN100340264C - Pharmaceutical composition for treating hypertension and hyperlipemia and its preparation method - Google Patents
Pharmaceutical composition for treating hypertension and hyperlipemia and its preparation method Download PDFInfo
- Publication number
- CN100340264C CN100340264C CNB2004100223580A CN200410022358A CN100340264C CN 100340264 C CN100340264 C CN 100340264C CN B2004100223580 A CNB2004100223580 A CN B2004100223580A CN 200410022358 A CN200410022358 A CN 200410022358A CN 100340264 C CN100340264 C CN 100340264C
- Authority
- CN
- China
- Prior art keywords
- parts
- hyperlipemia
- pharmaceutical composition
- lagotis
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a medicinal composition for treating hypertension and hyperlipoidemia and a preparation method thereof. The medicinal composition is prepared from the raw materials of tibetan medicine rhodiola root, Xuangoumu, phyllanthus emblica, nutmeg, herba lagotis, sappanwood and Jiazuihua. the clinical tests indicate that the medicine of the present invention can be used for treating hypertension and hyperlipoidemia and has favorable action. The medicinal composition of the present invention has scientific raw material prescription, easy acquirement for the raw materials, simple preparation method, no additive, good therapeutic efficacy, short treatment course and pure tibetan medicine preparation. The medicinal composition provides a new medicine selection for clinic.
Description
Technical field
The invention provides a kind of pharmaceutical composition for the treatment of hypertension, hyperlipemia and preparation method thereof, specifically, it is to be the pharmaceutical composition that raw material is made by Tibetan medicine.
Background technology
Hypertension is modal cardiovascular disease, and it is that 11.26% prevalence gathers way soon that the hypertension prevalence was once investigated by China.Show according to another Epidemiological study, present annual newly-increased 3,000,000 people's of China's hypertension speed development, only just there are 1,200,000 patients in the area, Shanghai, and the trend that continues increase is arranged.Hypertension can cause multiple diseases such as cardiac dilatation, heart failure, coronary heart disease, cerebral hemorrhage, cerebral thrombosis, the depletion of kidney merit, and the degree that these disease incidence rate and mortality rate and blood pressure increase is closely related.
Hyperlipidemia be since lipid metabolism or running one or more lipids of blood plasma are higher than normally be called hyperlipemia (Hyperlipemia, HP).Hyperlipemia often is a hyperlipoproteinemia (hyperlipoproteinemia), and it is meant that serum lipoprotein concentration raises.Hyperlipidemia can be classified according to the difference of lipoprotein component content again at present, comprise that hypercholesterolemia (Hypercholesterolemia), hypertriglyceridemia (Hypertriglyceridemia) and plyability hyperlipemia are one of main hazard factors that promotes atherosclerosis and the coronary atherosclerotic heart disease (CHD) that jeopardizes human health, and blood fat reducing can reduce the incidence rate of coronary atherosclerotic heart disease.Data shows according to statistics, and every hypercholesterolemia reducing level 1% can reduce the incidence rate of 2% myocardial infarction.
The generation of hypertension and development and hyperlipemia are closely related.A large amount of research datas show that many hypertensive patients are with lipid metabolic disorder, and the content of blood cholesterol and triglyceride significantly increases than the normal person, high density lipoprotein, cholesterol level are then lower, on the other hand, the also normal complicated hypertension of many hyperlipemias, both are cause effect relation.Hypertension and hyperlipemia belong to the important risk factor of coronary heart disease together, both and when depositing, evidence of coronary heart diseases is far beyond individual event person's height.Therefore, in the process of preventing and treating, mainly be to strengthen the life management at present, to keep on a diet, modest movement can increase endogenous pyrogen effectively, the intake of control salt.Adopt depressor, clinical research proves, the antihypertensive drugs that has can produce harmful effect to lipid metabolism, thereby become arteriosclerotic promoter, as the diuretic antihypertensive medicine, beta-blocker, angiotensin converting enzyme inhibitor, calcium ion antagonist etc., concerning hypertension and hyperlipemia and the patient that deposits, best medicine is a croak azoles piperazine, a receptor blocking agents such as urapidil, but they are blood pressure lowering both, help lipid metabolism again, but these medicines also there is apparent side effect, easily produce drug dependence, at present, adopt ethnic drug treatment hypertension, hyperlipemia does not still have relevant report.
Summary of the invention
It is the pharmaceutical composition of raw material for treating hypertension, hyperlipemia with Tibetan medicine, medical herbs that technical problem to be solved by this invention provides a kind of, and the present invention also provides this preparation of drug combination method.
The invention provides a kind of pharmaceutical composition for the treatment of hypertension, hyperlipemia, it is the medicament of being made by the following weight proportion raw material:
37~55 parts of Radix Rhodiolaes, 30~45 parts of XUANGOUMU, 28~39 parts of Fructus Phyllanthis, 27~36 parts of Semen Myristicaes, 25~36 parts of Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), 20~36 parts of Lignum Sappans, first mouth are spent 15~24 parts.
Further, it is the medicament of being made by the following weight proportion raw material:
39~50 parts of Radix Rhodiolaes, 33~40 parts of XUANGOUMU, 30~35 parts of Fructus Phyllanthis, 28~35 parts of Semen Myristicaes, 26~35 parts of Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), 23~34 parts of Lignum Sappans, first mouth are spent 16~20 parts.
Further, it is the medicament of being made by the following weight proportion raw material:
40 parts of Radix Rhodiolaes, 35 parts of XUANGOUMU, 31 parts of Fructus Phyllanthis, 29 parts of Semen Myristicaes, 27 parts of Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), 25 parts of Lignum Sappans, first mouth are spent 20 parts.
Wherein said medicament is decoction, powder, pill, capsule, tablet.
The present invention also provides this preparation of drug combination method, and it is to be prepared by the following step:
A, weighting raw materials by weight ratio: 37~55 parts of Radix Rhodiolaes, 30~45 parts of XUANGOUMU, 28~39 parts of Fructus Phyllanthis, 27~36 parts of Semen Myristicaes, 25~36 parts of Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), 20~36 parts of Lignum Sappans, first mouth are spent 15~24 parts.
B, a step medical material is broken into powder mixes, add the adjuvant of pharmaceutically accepting and make dosage form pharmaceutically commonly used.
The present invention also provides the purposes of this pharmaceutical composition in the medicine of preparation treatment hypertension, hyperlipemia.
The compatibility of material medicine of the present invention is according to Tibetan medicine's theory, in conjunction with clinical observation, inquire into research from aspects such as etiology and pathogenesis, the selection medicine is reasonable, select following medicine in the side for use, Radix Rhodiolae wherein: be the root and rhizome of Crassulaceae plant Radix Rhodiolae Rhodiola crenulata (Hook.f.etThoms.) H.Ohba, Tang Gute Radix Rhodiolae Rhodiola algida (ledeb) Fisch.Et Mey.Var.tangutica (Maxim.) S.H.Fu, has promoting blood circulation and detumescence, clearing away lung-heat to relieve cough, antipyretic analgesic, benefiting vital QI for tranquillizing, but and anti-hypoxia; XUANGOUMU is Tibetan medicine, sees Ge Er. Ge Sangzhaxi, " practical Tibetan medicine name storehouse ", Qinghai Nationalities Press, page 2; Fructus Phyllanthi, the fruit for euphorbia plant Fructus Phyllanthi Phyllanthus emblica L. has clearing away heat and cooling blood, promoting digestion and invigorating the stomach.Cure mainly hepatopathy, gallbladder disease, dyspepsia, oculopathy and " Baconic ", " red crust " etc. are sick; Semen Myristicae, for the kernel of myristicaceae plant Semen Myristicae Myristica fragrans Houtt., in the Tibetan medicine, effect is disappear " dragon ", stomach warming helps digestion.Cure mainly various heart diseases, dragon is sick; Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) claims Rhizoma Picrorhizae again, is goatweed Rhizoma Picrorhizae Picrorhiza scrophulariiflora Pennell rhizome, effect with heat clearing and inflammation relieving cures mainly " Baconic's wood brucellosis ", old eqpidemic disease and hypertension, arteries and veins heat, liver-heat, lung-heat, intestinal heat, diseases such as children's's diarrhea of heat type.Lignum Sappan: the dry duramen for leguminous plant Lignum Sappan Caesalpinia sappan L. has circulation of qi promoting, removing blood stasis with potent drugs, detumescence, analgesic effect; First mouth flower is Tibetan medicine, sees Ge Er. Ge Sangzhaxi, " practical Tibetan medicine name storehouse ", Qinghai Nationalities Press, the 76th page.
Crude drug Radix Rhodiolae of the present invention, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), first mouth flower, XUANGOUMU all derive from Qinghai-Tibet southeast edge, the area of tremble with fear, the Asia of height above sea level more than 4000 meters, Semen Myristicae, Lignum Sappan, the Chinese herbal medicine of Fructus Phyllanthi for using always; Radix Rhodiolae, Fructus Phyllanthi have benefiting QI for activating blood circulation removing heat from blood, suppressing hyperactive liver for descending adverse qi in the raw material of the present invention, " dragon " hemostasis, effect for reducing blood fat fall in clear " red crust ", are monarch drug; Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Semen Myristicae have flat contrary blood pressure lowering, dispel the wind that to separate expectorant be ministerial drug, and above-mentioned the monarch and his subjects match can suppressing hyperactive liver for descending adverse qi, the effect of blood pressure lowering, blood fat.First mouth flower, Lignum Sappan compatibility have phlegm reduction of blood circulation promoting, QI and blood and control, and treatment " Baconic ", expectorant, pleasant sending down the abnormal ascending QI are adjuvant drug, and it is messenger drug that liver is pricked a day loud, high-pitched sound, and priming is descending, prevents hemorrhage effect.Full presciption medicine thing compatibility uses, can benefiting qi and removing blood stasis, and heat clearing away, suppressing the hyperactive liver and subsiding YANG, blood pressure lowering, reduction intracranial pressure edema increase the oxygen confession, and blood circulation promoting and blood stasis dispelling are arranged, and improve circulation, help preventing hemorrhage, reach the effect of treatment hypertension, hyperlipidemia.
By clinical trial proof treatment hypertension, hyperlipidemia, effect is remarkable, and because medicine of the present invention comes from the high altitude localities, plateau more, the raw material consumption is few, cost is low, is easy to get, and preparation method is simple, no any additives, curative effect is reliable, and the Nantural non-toxic side effect is pure Tibetan medicinal preparation.
Obviously, according to foregoing of the present invention,,, can also make modification, replacement or the change of other various ways not breaking away under the above-mentioned basic fundamental thought of the present invention prerequisite according to the ordinary skill knowledge and the customary means of this area.
The specific embodiment of form is described in further detail foregoing of the present invention again by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.
The specific embodiment
Embodiment 1 preparation of drug combination of the present invention
A, weighting raw materials by weight ratio: Radix Rhodiolae 55g, XUANGOUMU 45g, Fructus Phyllanthi 39g, Semen Myristicae 36g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 36g, Lignum Sappan 36g, first mouth flower 24g;
With the powder that embodiment 1 makes, add 1% adjuvants pharmaceutically commonly used such as magnesium stearate, can make tablet or encapsulated by tabletting, make capsule.
Embodiment 2 preparation of drug combination of the present invention
A, weighting raw materials by weight ratio: Radix Rhodiolae 40g, XUANGOUMU 35g, Fructus Phyllanthi 31g, Semen Myristicae 29g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 27g, Lignum Sappan 25g, first mouth flower 20g;
B, a step medical material is broken into powder mixes, make powder.
With the powder that embodiment 2 makes, add 1% adjuvants pharmaceutically commonly used such as magnesium stearate, can make tablet or encapsulated by tabletting, make capsule.
Embodiment 3 preparation of drug combination of the present invention
A, weighting raw materials by weight ratio: Radix Rhodiolae 37g, XUANGOUMU 30g, Fructus Phyllanthi 28g, Semen Myristicae 27g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 25g, Lignum Sappan 20g, first mouth flower 15g;
B, a step medical material is broken into powder mixes, make powder.
With the powder that embodiment 3 makes, add 1% adjuvants pharmaceutically commonly used such as magnesium stearate, can make tablet or encapsulated by tabletting, make capsule.
Below prove beneficial effect of the present invention by clinical trial.
The clinical trial of experimental example 1 pharmaceutical composition of the present invention
Clinical trial according to the present invention in seven of pharmaceutical composition years is added up, is analyzed, and its result is as follows:
Physical data:
200 examples are organized in treatment, male 124 examples, women 76 examples, the hypertension in 1~5 year of the course of disease, hyperlipemic patients.
Therapeutic Method: take medicine of the present invention, every day 3 times, each 1~2g, 28 days is a course of treatment.
Therapeutic effect:
Case load | The routine number of fully recovering | Produce effects example number | Invalid routine number | Total effective rate |
200 | 80% | 20% | 0 | 100% |
By above-mentioned clinical trial, prove absolutely that medicine of the present invention can be used for treating hypertension, hyperlipidemia, have good effect, drug regimen raw material prescription of the present invention is scientific and reasonable, and raw material is easy to get, preparation method is simple, no any additives, therapeutic effect is good, short treating period, be pure Tibetan medicinal preparation, provide a kind of new medication to select for clinical.
Claims (7)
1, a kind of pharmaceutical composition for the treatment of hypertension, hyperlipemia is characterized in that: it is the medicament of being made by the following weight proportion raw material:
37~55 parts of Radix Rhodiolaes, 30~45 parts of XUANGOUMU, 28~39 parts of Fructus Phyllanthis, 27~36 parts of Semen Myristicaes, 25~36 parts of Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), 20~36 parts of Lignum Sappans, first mouth are spent 15~24 parts.
2, the pharmaceutical composition of treatment hypertension according to claim 1, hyperlipemia is characterized in that: it is the medicament of being made by the following weight proportion raw material:
39~50 parts of Radix Rhodiolaes, 33~40 parts of XUANGOUMU, 30~35 parts of Fructus Phyllanthis, 28~35 parts of Semen Myristicaes, 26~35 parts of Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), 23~34 parts of Lignum Sappans, first mouth are spent 16~20 parts.
3, the pharmaceutical composition of treatment hypertension according to claim 1, hyperlipemia is characterized in that: it is the medicament of being made by the following weight proportion raw material:
40 parts of Radix Rhodiolaes, 35 parts of XUANGOUMU, 31 parts of Fructus Phyllanthis, 29 parts of Semen Myristicaes, 27 parts of Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), 25 parts of Lignum Sappans, first mouth are spent 20 parts.
4, according to the pharmaceutical composition of claim 1,2,3 described treatment hypertension, hyperlipemia, it is characterized in that: described medicament is decoction, powder, pill, capsule, tablet.
5, the preparation of drug combination method of the described treatment hypertension of claim 1, hyperlipemia, it is to be prepared by the following step:
A, weighting raw materials by weight ratio: 37~55 parts of Radix Rhodiolaes, 30~45 parts of XUANGOUMU, 28~39 parts of Fructus Phyllanthis, 27~36 parts of Semen Myristicaes, 25~36 parts of Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), 20~36 parts of Lignum Sappans, first mouth are spent 15~24 parts;
B, a step medical material is broken into powder mixes, add the adjuvant of pharmaceutically accepting and make dosage form pharmaceutically commonly used.
6, the purposes of the described pharmaceutical composition of claim 1 in the hypertensive medicine of preparation treatment.
7, the purposes of the described pharmaceutical composition of claim 1 in the medicine of preparation treatment hyperlipidemia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100223580A CN100340264C (en) | 2004-04-21 | 2004-04-21 | Pharmaceutical composition for treating hypertension and hyperlipemia and its preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100223580A CN100340264C (en) | 2004-04-21 | 2004-04-21 | Pharmaceutical composition for treating hypertension and hyperlipemia and its preparation method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1689603A CN1689603A (en) | 2005-11-02 |
CN100340264C true CN100340264C (en) | 2007-10-03 |
Family
ID=35345557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100223580A Expired - Fee Related CN100340264C (en) | 2004-04-21 | 2004-04-21 | Pharmaceutical composition for treating hypertension and hyperlipemia and its preparation method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100340264C (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104258026A (en) * | 2014-09-16 | 2015-01-07 | 苏州市天灵中药饮片有限公司 | Blood fat-reducing traditional Chinese medicine composition and preparation method thereof |
CN104336262A (en) * | 2014-11-16 | 2015-02-11 | 久美彭措 | Insomnia-resistant substitute tea prepared by combining edible plants serving as components |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1350859A (en) * | 2000-10-30 | 2002-05-29 | 高林 | Medicine for preventing and treating cardiovascular and cerebrovascular diseases |
-
2004
- 2004-04-21 CN CNB2004100223580A patent/CN100340264C/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1350859A (en) * | 2000-10-30 | 2002-05-29 | 高林 | Medicine for preventing and treating cardiovascular and cerebrovascular diseases |
Also Published As
Publication number | Publication date |
---|---|
CN1689603A (en) | 2005-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102058817B (en) | Tibetan medicinal preparation for treating liver diseases | |
CN1136874C (en) | Composite medicine for treating hyperlipemia | |
CN1628768A (en) | Medicine for treating gout affection and its symptoms | |
CN108853433A (en) | A kind of Chinese medicine and preparation method thereof for treating diabetic nephropathy | |
CN100340264C (en) | Pharmaceutical composition for treating hypertension and hyperlipemia and its preparation method | |
CN1302800C (en) | Chinese traditional medicine preparation for curing gastric ulcer | |
CN1895593A (en) | Medicine for treating acne and its preparation | |
CN101062097A (en) | Compound for improving and treating fatty liver disease | |
CN1478497A (en) | Medicine for treating fatty liver | |
CN1233364C (en) | Chinese medicine for treating digestive ulcerating sore and its preparation method | |
CN1299732C (en) | Chinese medicine preparation for treating fatty liver | |
CN1927381A (en) | Medicine comprising rilmenidine | |
CN1050045C (en) | Traditional Chinese medicine-Liu's Hua'ai huixiangdan for treating carcinoma of esophagus | |
CN1891267A (en) | Chinese medicine for treating atrophic arthritis | |
CN101066425A (en) | Chinese medicine prepn for treating ungual mycosis | |
CN1911277A (en) | Medicine for treating leukopenia | |
CN1772149A (en) | Chinese medicine composition for treating coronary heart disease and its prepn | |
CN1293914C (en) | Health care medicinal composition for improving sleeping and preparation preocess thereof | |
CN103142732B (en) | Traditional Chinese medicine composition for treating hypertension | |
CN1212150C (en) | Medicine for treating virus hepatitis and its preparation method | |
CN1231568C (en) | Meridians-activating and kidney-nourishing wine | |
CN1255149C (en) | Combination of medication | |
CN1602921A (en) | Medicine for treating diabetes and its preparing process | |
CN1958031A (en) | New application of purple fragrant plantainlily root in preparing medication | |
CN104815024A (en) | Capsule for treating gout and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071003 |
|
RR01 | Reinstatement of patent right |
Former decision: cessation of patent right due to non-payment of the annual fee Former decision publication date: 20100804 |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071003 Termination date: 20130421 |